All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-08-29T12:25:37.000Z

FDA approval sought for once-weekly carfilzomib

Aug 29, 2018
Share:

Bookmark this article

Amgen have submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA), for once-weekly dosing of carfilzomib (Kyprolis®) in combination with dexamethasone, in patients with relapsed and refractory multiple myeloma (RRMM).

The application was based on data from the phase III ARROW study, presented by Maria-Victoria Mateos at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting – read here and listen here. The study was conducted in collaboration with Philippe Moreau from the University Hospital of Nantes, Nantes, France, and was published in The Lancet Oncology on 1 June 2018.

In this trial, carfilzomib was administered at a dose of 70 mg/m2 once-weekly (along with dexamethasone), instead of the usual twice-weekly dose of 27 mg/m2. The study showed that patients receiving the once-weekly dosing had a median progression-free survival (PFS) of 11.2 months compared to 7.6 months for twice-weekly dosing. In addition, the overall response rate (ORR) in patients in the once-weekly arm was 62.9% (95% CI, 56.5-69.0), with 7% of patients also achieving a complete response or better, compared to an ORR of 40.8% (95% CI, 35.5-47.3) in the twice-weekly arm (P <.0001) and only 2% of patients in this arm achieving a CR. There was only a moderate increase in grade 3 (or greater) adverse events (68% vs 62%) for the once-weekly compared to twice-weekly, with complaints including anemia, pneumonia, diarrhea, and thrombocytopenia.

Given that this new regimen offers both improved efficacy and improved convenience for patients, there will be many people eagerly awaiting approval.

  1. https://www.targetedonc.com/news/onceweekly-carfilzomib-submitted-for-fda-approval-in-myeloma
  2. Moreau P. et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. The Lancet Oncology. June 2018. DOI:https://doi.org/10.1016/S1470-2045(18)30354-1

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox